375 related articles for article (PubMed ID: 23533263)
1. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
2. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
5. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
[TBL] [Abstract][Full Text] [Related]
6. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
7. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
8. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Vivanco I; Robins HI; Rohle D; Campos C; Grommes C; Nghiemphu PL; Kubek S; Oldrini B; Chheda MG; Yannuzzi N; Tao H; Zhu S; Iwanami A; Kuga D; Dang J; Pedraza A; Brennan CW; Heguy A; Liau LM; Lieberman F; Yung WK; Gilbert MR; Reardon DA; Drappatz J; Wen PY; Lamborn KR; Chang SM; Prados MD; Fine HA; Horvath S; Wu N; Lassman AB; DeAngelis LM; Yong WH; Kuhn JG; Mischel PS; Mehta MP; Cloughesy TF; Mellinghoff IK
Cancer Discov; 2012 May; 2(5):458-71. PubMed ID: 22588883
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
[TBL] [Abstract][Full Text] [Related]
13. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
14. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
15. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
17. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Nathanson DA; Gini B; Mottahedeh J; Visnyei K; Koga T; Gomez G; Eskin A; Hwang K; Wang J; Masui K; Paucar A; Yang H; Ohashi M; Zhu S; Wykosky J; Reed R; Nelson SF; Cloughesy TF; James CD; Rao PN; Kornblum HI; Heath JR; Cavenee WK; Furnari FB; Mischel PS
Science; 2014 Jan; 343(6166):72-6. PubMed ID: 24310612
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
